Why the Form of Your Supplement Matters More Than the Dose

Bioavailability determines how much of a supplement your body actually absorbs. The chemical form, not the milligram count, is what counts.

Molecular structures representing different supplement formulations and bioavailability

The 500-Milligram Illusion

A customer stands in the supplement aisle comparing two bottles of magnesium. One contains 500 mg of magnesium oxide per capsule. The other contains 200 mg of magnesium bisglycinate. The choice seems obvious: more milligrams for the same price. She picks the 500 mg bottle, pays, and goes home confident she’s made the rational decision. She hasn’t. That 500 mg capsule will deliver a fraction of the magnesium her body can actually use, while the 200 mg alternative would have put more mineral into her bloodstream. This scenario plays out millions of times a day across North America, driven by a widespread misunderstanding of how oral supplements work. The milligram number on the label tells you what’s in the capsule. It tells you almost nothing about what reaches your cells.

The concept that governs this gap between ingestion and absorption is called bioavailability, and it’s the single most important factor in whether a supplement does anything at all. Bioavailability refers to the proportion of an ingested substance that enters systemic circulation in a form the body can use. For intravenous drugs, bioavailability is 100 percent by definition. For oral supplements, it can range anywhere from less than 1 percent to above 90 percent, depending on the compound’s chemical form, the carrier matrix, co-administered substances, and the individual’s own gut physiology. Understanding why requires a brief tour of what happens between swallowing a capsule and actually benefiting from its contents.

The Gauntlet Between Your Mouth and Your Bloodstream

When you swallow a supplement, it enters an obstacle course that most pharmaceutical chemists would describe as brutally efficient at destroying things. The stomach’s hydrochloric acid begins breaking down the capsule and its contents, but pH extremes can degrade sensitive compounds before they ever reach the absorptive surface of the small intestine. Roughly 90 percent of nutrient absorption occurs in the small intestine, where compounds must cross the intestinal epithelium, a barrier lined with tight junctions, efflux transporters that actively pump foreign molecules back into the gut lumen, and a mucous layer that slows diffusion. Compounds that survive this crossing then enter the portal vein and travel directly to the liver, where cytochrome P450 enzymes, particularly CYP3A4 and CYP2D6, metabolize a significant fraction before the substance ever reaches general circulation (Herman & Santos, StatPearls, 2023). This hepatic processing is called first-pass metabolism, and for many compounds it eliminates 70 to 95 percent of the ingested dose.

Two physical properties largely determine how well a compound survives this gauntlet: solubility and permeability. The Biopharmaceutics Classification System categorizes drugs and nutrients into four classes based on these properties. Class I compounds, high solubility and high permeability, absorb easily. Class IV compounds, low solubility and low permeability, absorb terribly. Many popular supplement ingredients, including curcumin, CoQ10, and astaxanthin, fall squarely into the problem categories, which means their raw forms are poorly absorbed regardless of how many milligrams you pack into a capsule. The formulation science that addresses these limitations is where the real action is, and where consumers need to pay closer attention.

Magnesium: A Case Study in How Form Changes Everything

Magnesium supplementation provides the clearest illustration of why chemical form matters. Magnesium oxide, the form found in most cheap supplements, contains about 60 percent elemental magnesium by weight, which looks impressive on labels. But its fractional absorption rate is around 4 percent in most studies, meaning a 500 mg capsule delivers roughly 12 mg of usable magnesium to the bloodstream (Firoz & Graber, Magnesium Research, 2001). Magnesium citrate performs considerably better, with absorption rates in the range of 25 to 30 percent. Magnesium bisglycinate, a chelated form bound to the amino acid glycine, achieves even higher absorption because the glycine chelate is recognized by amino acid transporters in the intestinal wall, giving it a second absorption pathway beyond passive diffusion (Schuette et al., Journal of the American College of Nutrition, 1994). A December 2024 randomized crossover trial comparing multiple magnesium forms found that plasma magnesium levels increased at multiple time points following citrate and oxide administration, but the kinetic profiles differed substantially, with organic chelated forms showing more sustained elevation (Nutrients, 2024).

The tolerability difference is equally striking. Magnesium oxide’s poor absorption means most of it stays in the gut lumen, where it draws water osmotically and causes the diarrhea that so many magnesium users experience. Chelated forms cause far less gastrointestinal distress precisely because more of the mineral crosses the intestinal wall instead of sitting in the colon. A person taking 400 mg of magnesium bisglycinate will absorb more magnesium, with fewer side effects, than someone taking 800 mg of magnesium oxide. The dose was never the problem. The form was.

The Lipid-Soluble Problem: Curcumin, CoQ10, and Astaxanthin

Fat-soluble compounds face a distinct set of absorption challenges because they don’t dissolve readily in the aqueous environment of the gastrointestinal tract. Curcumin, the active polyphenol in turmeric, is the poster child for this problem. Native curcumin has such poor oral bioavailability that a 2023 review in ACS Omega described it as “virtually undetectable in plasma” after standard oral dosing (Schiborr et al., ACS Omega, 2023). The compound is poorly soluble, rapidly metabolized by phase II conjugation enzymes, and actively pumped back out of enterocytes by efflux transporters. Taking more milligrams of plain curcumin powder doesn’t meaningfully change this equation.

What does change it is formulation technology. Co-administration with piperine, the alkaloid in black pepper, inhibits glucuronidation in the gut wall and liver, which was initially reported to increase curcumin bioavailability by 2,000 percent in a widely cited 1998 study (Shoba et al., Planta Medica, 1998). Subsequent clinical data has been more mixed, with some trials finding the AUC of curcumin with and without piperine did not differ to a meaningful degree (Flory et al., Molecular Nutrition & Food Research, 2021). The real bioavailability gains have come from physical reformulation. Micellar curcumin formulations have demonstrated a 57-fold increase in plasma AUC compared to native curcumin, while gamma-cyclodextrin complexation achieved a 30-fold improvement in the same crossover trial design. Phytosomal curcumin, which complexes the molecule with phosphatidylcholine to improve membrane transit, has shown roughly 7.5-fold AUC increases in healthy adults, and a clinical trial using a phytosomal preparation with phosphatidylserine and piperine demonstrated marked improvements in fasting plasma insulin and HOMA index in overweight subjects over 56 days (Panahi et al., European Journal of Nutrition, 2019). The hierarchy here is clear: delivery vehicle matters enormously, and the differences aren’t marginal.

CoQ10 tells a similar story with an additional twist. The compound exists in two forms: ubiquinone (oxidized) and ubiquinol (reduced). Marketing for ubiquinol supplements often claims superior absorption, and there is supporting evidence: after four weeks of supplementation, plasma CoQ10 reached 4.3 micrograms per milliliter with ubiquinol versus 2.5 with ubiquinone in one comparative trial (Lopez-Lluch et al., Antioxidants, 2019). But a 2020 review in Antioxidants found that failure to subject crystalline CoQ10 to proper crystal dispersion during manufacturing reduced bioavailability by approximately 75 percent regardless of whether the form was ubiquinone or ubiquinol (Mantle & Dybring, Antioxidants, 2020). The formulation technique, specifically how the crystals are dispersed into carrier lipids, may matter more than the oxidation state of the molecule itself. This is an inconvenient finding for supplement marketers who charge a steep premium for ubiquinol without disclosing their crystal dispersion methods.

Astaxanthin, a carotenoid antioxidant derived from microalgae, faces comparable challenges. As a highly lipophilic molecule, its absorption from dry powder formulations is minimal. A human pharmacokinetic study found that incorporating astaxanthin into a lipid-based matrix of glycerol mono- and di-oleate improved oral bioavailability 3.7-fold compared to algae-dextrin reference capsules (Odeberg et al., European Journal of Pharmaceutical Sciences, 2003). Sustained-release lipid matrix formulations have further improved absorption while reducing the wide person-to-person variability that plagues carotenoid supplementation (Madhavi et al., JACS, 2018).

Iron: When Better Absorption Also Means Fewer Side Effects

Iron supplementation offers a case where improved bioavailability directly translates to reduced harm. Ferrous sulfate, the standard clinical form, is cheap and contains high elemental iron, but it’s notorious for gastrointestinal side effects: nausea, constipation, abdominal cramping. These occur because much of the iron isn’t absorbed and instead irritates the gut lining and feeds pathogenic bacteria in the colon. Ferrous bisglycinate, an amino acid chelate, achieves geometric mean iron absorption rates of 6.0 percent compared to 1.7 percent for ferrous sulfate when consumed with whole maize, a 3.5-fold difference (Bovell-Benjamin et al., American Journal of Clinical Nutrition, 2000). In pregnant women with iron deficiency anemia, bisglycinate demonstrated greater efficacy in raising hemoglobin levels with fewer gastrointestinal complaints, and compliance rates were higher because women could tolerate the supplement (Parisi et al., Nutrients, 2022). A 2023 meta-analysis of randomized controlled trials confirmed that ferrous bisglycinate effectively raises hemoglobin and ferritin concentrations with a better side-effect profile, though some trials comparing lower-dose bisglycinate against higher-dose ferrous sulfate have produced mixed results, reminding us that dose still matters within a given form (Li et al., PMC, 2023).

The New Formulation Toolbox

The past decade has produced a set of delivery technologies that are rapidly moving from pharmaceutical R&D into the consumer supplement space. Liposomal delivery, which encapsulates active compounds within phospholipid bilayer vesicles that mimic cell membranes, has accumulated the strongest clinical evidence. A 2024 double-blind, placebo-controlled randomized trial found that 500 mg of liposomal vitamin C produced 27 percent higher peak plasma concentrations and 21 percent greater total exposure (AUC) than a standard vitamin C tablet, with even more pronounced differences in leukocyte uptake (Gopi & Balakrishnan, European Journal of Nutrition, 2024). A scoping review identified nine studies showing 1.2- to 5.4-fold higher peak plasma levels and 1.3- to 7.2-fold higher AUC values for liposomal versus non-liposomal ascorbate formulations, though the review noted that clinical outcome data linking these pharmacokinetic advantages to actual health endpoints remains sparse (PMC, 2025).

Phytosomal technology, which complexes active molecules with phosphatidylcholine to form a compound that is both lipophilic and hydrophilic, has shown particular promise for polyphenols. Cyclodextrin complexation uses ring-shaped sugar molecules with hydrophobic interiors that can encapsulate poorly soluble compounds, improving their aqueous solubility without organic solvents. The 30-fold bioavailability improvement achieved with gamma-cyclodextrin curcumin is one of the largest gains documented for any oral formulation strategy. Nano-emulsions, which reduce lipid droplet size below 200 nanometers, dramatically increase surface area for absorption and have shown particular utility for carotenoids and fat-soluble vitamins. These aren’t theoretical curiosities anymore. They’re appearing on supplement shelves, and the companies using them are starting to produce the pharmacokinetic data to back up their label claims.

Reading Labels Like a Pharmacologist

The practical challenge for consumers is that supplement labels aren’t required to disclose bioavailability data, and most don’t. Under the 1994 Dietary Supplement Health and Education Act (DSHEA), supplements in the United States don’t require pre-market approval for efficacy. Canada’s Natural Health Products Regulations are somewhat stricter, requiring product licensing and evidence of safety, but bioavailability testing against comparator forms isn’t mandated. The result is a market where a company can sell 500 mg of magnesium oxide at the same price point as 200 mg of magnesium bisglycinate, and most consumers will choose the higher number without understanding they’re getting less usable mineral. A 2015 analysis in the American Journal of Public Health described the U.S. regulatory framework for supplements as “too little, too late,” noting that FDA enforcement is almost entirely post-market and complaint-driven (Cohen, AJPH, 2015).

What should a skeptical consumer look for? The specific chemical form should be listed in the Supplement Facts panel or the ingredient list, not just the generic nutrient name. “Magnesium” is insufficient; you need to see “magnesium bisglycinate” or “magnesium citrate.” For lipid-soluble compounds, the delivery technology matters: look for terms like “liposomal,” “phytosomal,” “micellar,” or “nano-emulsified,” and check whether the manufacturer cites any pharmacokinetic studies on their specific formulation, not just the generic technology. Third-party certifications from organizations like NSF International, USP, or ConsumerLab verify that the product contains what it claims, though they don’t typically test comparative bioavailability. The most transparent supplement companies now publish their own pharmacokinetic trials or reference peer-reviewed data on their specific formulation, and this kind of transparency should be the minimum standard consumers demand.

Where the Evidence Points

The pharmacokinetics of supplement absorption have been well-characterized for decades, but the supplement industry has been slow to apply what pharmaceutical science already knows. The reason is partly economic: bioavailable forms cost more to manufacture, and consumers have been trained to compare milligram counts rather than absorption profiles. That’s beginning to change as clinical data accumulates showing that formulation differences aren’t small. A 57-fold difference in curcumin absorption. A 3.7-fold difference in astaxanthin uptake. A 75 percent bioavailability loss from poor crystal dispersion in CoQ10. These aren’t rounding errors. They’re the difference between a supplement that works and one that’s expensive urine, to borrow the old dismissive phrase that, for poorly formulated products, is actually accurate.

The most important shift consumers can make isn’t buying more supplements. It’s learning that the milligram number on the front of the bottle is the beginning of the story, not the end of it. A smaller dose of a well-formulated, highly bioavailable compound will outperform a megadose of a cheap form every time. The science on this point isn’t ambiguous, and the gap between what the evidence shows and what the average consumer believes represents one of the most consequential information failures in preventive health. As delivery technologies like liposomal encapsulation, cyclodextrin complexation, and nano-emulsion continue to mature and accumulate clinical validation, the supplements of 2030 will look very different from those of 2020. The question is whether labeling standards and consumer education will keep pace, or whether the milligram myth will persist, keeping shelves stocked with products that impress on paper and disappoint in the bloodstream.

References

  1. Herman, T.F. & Santos, C. “First-Pass Effect.” StatPearls, NCBI Bookshelf, 2023. www.ncbi.nlm.nih.gov/books/NBK551679/

  2. Firoz, M. & Graber, M. “Bioavailability of US commercial magnesium preparations.” Magnesium Research, 2001.

  3. Schuette, S.A. et al. “Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection.” Journal of the American College of Nutrition, 1994. pubmed.ncbi.nlm.nih.gov/7815675/

  4. Nutrients. “Comparative Clinical Study on Magnesium Absorption and Side Effects After Oral Intake of Microencapsulated Magnesium Versus Other Magnesium Sources.” Nutrients, 16(24), 4367, 2024. www.mdpi.com/2072-6643/16/24/4367

  5. Schiborr, C. et al. “Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?” ACS Omega, 2023. pubs.acs.org/doi/10.1021/acsomega.2c07326

  6. Shoba, G. et al. “Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers.” Planta Medica, 64(4), 353-356, 1998.

  7. Flory, S. et al. “Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability.” Molecular Nutrition & Food Research, 2021. onlinelibrary.wiley.com/doi/10.1002/mnfr.202100613

  8. Panahi, Y. et al. “Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices.” European Journal of Nutrition, 2019. link.springer.com/article/10.1007/s00394-019-01916-7

  9. Mantle, D. & Dybring, A. “Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism.” Antioxidants, 9(5), 386, 2020. www.mdpi.com/2076-3921/9/5/386

  10. Lopez-Lluch, G. et al. “Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals.” Antioxidants, 2019. pmc.ncbi.nlm.nih.gov/articles/PMC7146408/

  11. Odeberg, J.M. et al. “Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations.” European Journal of Pharmaceutical Sciences, 19(4), 299-304, 2003.pubmed.ncbi.nlm.nih.gov/12885395/

  12. Madhavi, D. et al. “A Study on the Bioavailability of a Proprietary, Sustained-release Formulation of Astaxanthin.” Journal of the American College of Nutrition, 2018. pmc.ncbi.nlm.nih.gov/articles/PMC6396763/

  13. Bovell-Benjamin, A.C. et al. “Iron absorption from ferrous bisglycinate and ferric trisglycinate in whole maize.” American Journal of Clinical Nutrition, 2000.

  14. Parisi, F. et al. “Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women.” Nutrients, 14(3), 452, 2022. https://www.mdpi.com/2072-6643/14/3/452

  15. Li, S. et al. “The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis.” PMC, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10331582/

  16. Gopi, S. & Balakrishnan, P. “Liposomal delivery enhances absorption of vitamin C into plasma and leukocytes.” European Journal of Nutrition, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11519160/

  17. PMC. “Do Liposomal Vitamin C Formulations Have Improved Bioavailability? A Scoping Review.” PMC, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12163105/

  18. Cohen, P.A. “Too Little, Too Late: Ineffective Regulation of Dietary Supplements in the United States.” American Journal of Public Health, 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4330859/

  19. Cyclodextrin Inclusion Complexes for Improved Drug Bioavailability and Activity. Pharmaceutics, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10534465/